Last reviewed · How we verify
NCT03827785
Transcranial Magnetic Stimulation for Treatment of Methamphetamine Dependence
NA trial testing rTMS treatment group in Methamphetamine-dependence in 100 participants. Completed in 12 December 2020.
1 September 2020
Quick facts
| Lead sponsor | Shanghai Mental Health Center |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | triple |
| Primary purpose | treatment |
| Enrollment | 100 |
| Start date | 1 February 2019 |
| Primary completion | 1 September 2020 |
| Estimated completion | 12 December 2020 |
| Sites | 1 location across China |
Drugs / interventions tested
- rTMS treatment group
- sham rTMS treatment group
Conditions studied
- Methamphetamine-dependence — all drugs for Methamphetamine-dependence →
Sponsor
Shanghai Mental Health Center — full company profile →
Who can join
Adults 18 to 45, any sex, with Methamphetamine-dependence. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Repetitive transcranial magnetic stimulation (rTMS) was used to treat methamphetamine (MA) addiction in previous studies, while the evidence-based protocols still required. The aim of this research is to evaluating the effectiveness and safety of rTMS treatment in improving the days of abstinence maintenance. In addition, treatment effect on cognitive impairment, psychological craving and depression are also evaluated during the study.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03827785
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Methamphetamine-dependence
Currently open trials in the same condition.
- NCT06701487 — Role of Pavlovian Mechanisms for Control Over Substance Use · recruiting
- NCT06233799 — Trial of Naltrexone/Bupropion for the Treatment of Methamphetamine Use Disorder · Phase 3 · recruiting
- NCT06027814 — MHealth Incentivized Adherence Plus Patient Navigation · NA · active not recruiting
- NCT06434818 — Enhanced Digital-Chemosensory-Based Olfactory Training for Remote Management of Substance Use Disorders · Phase 2 · recruiting
- NCT05162391 — Inflammation in Methamphetamine and STIs (IMSTI) · NA · active not recruiting
Other Shanghai Mental Health Center trials
Trials by the same sponsor.
- NCT07480408 — Neural Mechanisms of the Sensorymotor Circuit in Sensory Phenomena in OCD · NA · not yet recruiting
- NCT07479771 — tTIS Targeted of the Striatum as an Intervention for MUD Patients · NA · not yet recruiting
- NCT07472673 — Transcranial Temporal Interference Stimulation Targeted of the Amygdala as an Intervention for Alcohol Use Disorder Pati · NA · not yet recruiting
- NCT07484750 — Efficacy and Influencing Factors of Mindfulness-Based Exposure Group Therapy for OCD · NA · recruiting
- NCT07311655 — Validation of the Accuracy of an AI-Based System for Diagnosing Anxiety Disorders · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03827785 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Shanghai Mental Health Center
- Last refreshed: 16 September 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03827785.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing